Technical Analysis of Aveanna Healthcare: Aveanna Healthcare Holdings Inc. (AVAH) has reached a significant support level, with its 50-day moving average crossing above the 200-day moving average, indicating a potential bullish trend known as a "golden cross."
Understanding Golden Cross: A golden cross occurs when a short-term moving average surpasses a long-term moving average, typically signaling a positive trend reversal after a downtrend.
Recent Performance and Outlook: AVAH has seen an 88.6% increase in the past four weeks and is rated #1 (Strong Buy) on the Zacks Rank, suggesting it may be positioned for further gains due to positive earnings revisions.
Investment Opportunities: The article highlights that AVAH is among stocks recommended by Zacks experts, which have historically shown significant returns, presenting a potential opportunity for investors looking to capitalize on emerging stocks.
AVAH
$8.84+Infinity%1D
Analyst Views on AVAH
Wall Street analysts forecast AVAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVAH is 10.44 USD with a low forecast of 9.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast AVAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVAH is 10.44 USD with a low forecast of 9.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.890
Low
9.00
Averages
10.44
High
12.50
Current: 8.890
Low
9.00
Averages
10.44
High
12.50
BMO Capital
Outperform
initiated
$11
2025-11-12
Reason
BMO Capital
Price Target
$11
2025-11-12
initiated
Outperform
Reason
BMO Capital initiated coverage of Aveanna with an Outperform rating and $11 price target. Shares are up about 130% since early August on strong Q2 and Q3 results fueled by state reimbursement increases, preferred payer expansion, and disciplined cost control, which also lowered leverage, the analyst tells investors in a research note. While future Medicaid rate hikes may be limited, ongoing payer conversions, cost discipline, and potential M&A underpin expectations for 10+ long-term EBITDA growth, the firm says.
UBS
AJ Rice
Neutral
maintain
$9
2025-11-07
Reason
UBS
AJ Rice
Price Target
$9
2025-11-07
maintain
Neutral
Reason
UBS analyst AJ Rice raised the firm's price target on Aveanna to $9.50 from $9 and keeps a Neutral rating on the shares.
Jefferies
Buy
maintain
$11
2025-10-28
Reason
Jefferies
Price Target
$11
2025-10-28
maintain
Buy
Reason
Jefferies raised the firm's price target on Aveanna to $12.50 from $11 and keeps a Buy rating on the shares after the company announced a secondary offering of 10M shares along with preliminary Q3 results last week. The preliminary results reflect management's success in securing favorable reimbursement, driving volume and EBITDA growth, the analyst tells investors.
RBC Capital
Ben Hendrix
Sector Perform
maintain
$8 -> $10
2025-10-23
Reason
RBC Capital
Ben Hendrix
Price Target
$8 -> $10
2025-10-23
maintain
Sector Perform
Reason
RBC Capital analyst Ben Hendrix raised the firm's price target on Aveanna to $10 from $8 and keeps a Sector Perform rating on the shares. The company reported strong preliminary Q3 results that came in well ahead of expectations, the analyst tells investors in a research note. The firm also believes J.H. Whitney's recently priced sale of 10M shares should begin to ease the stock's private equity and share liquidity overhang.
About AVAH
Aveanna Healthcare Holdings Inc. is a provider of diversified home care platforms. Its segments include Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS segment includes private duty nursing (PDN) services, as well as pediatric therapy services. HHH segment includes home health services, as well as hospice and specialty program services. Its home health services involve the provision of in-home services to its patients by its clinicians, which include nurses, therapists, social workers and home health aides. Its hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Medical Solutions segment offers a line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. It also provides case management services to assist families and patients by coordinating the provision of services between insurers and other healthcare providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
